RxDoctor Payments Data

Lyudmila Nikolaychook, DO

Surgery · Montgomery, ALNPI 1578794533

Payments from drug & device makers

$1,698in general payments, 2019–2025

Across 83 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cumberland Pharmaceuticals, Inc.$364
  • Paratek Pharmaceuticals, Inc.$274
  • Solventum Corporation$191
  • Smith+Nephew$161
  • Urgo Medical North America, LLC$151
  • AbbVie$119
  • plus $438 from 9 others

What the payments were for

  • Food & beverage$1,698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,698 in reported general payments places this provider in the 45th percentile of 382 surgery providers in Alabama.

See all surgery providers in Alabama

Medicare billing

Part B allowed, 2024
$23,976
Medicare patients
108
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.36$152,301
Linezolid49$4,315
Cefepime Hcl19$2,707
SsdSilver Sulfadiazine81$2,592
Daptomycin14$2,399
Doxycycline Monohydrate77$2,393
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam23$1,552
Levofloxacin75$1,513
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$704
Silver Sulfadiazine19$416
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim37$383
Sodium Chloride0.9 % Sodium Chloride18$230
Methylprednisolone12$150
Fluconazole24$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$161$152,30136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 382 surgery providers in Alabama.

Other surgery in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →